Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
46 hedge funds and large institutions have $180M invested in Evelo Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 27 closing their positions.
312% more call options, than puts
Call options by funds: $210K | Put options by funds: $51K
12% more capital invested
Capital invested by funds: $161M → $180M (+$19.3M)
32% less funds holding
Funds holding: 68 → 46 (-22)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
70% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$63.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.9M |
| 3 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$6.89M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$4.76M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$794K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.67M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.12M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$997K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$498K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$470K |
EVLO Hedge Fund Activity: Q2 2022 in Review
46 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2022, worth a combined $180M — up 12% from $161M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of EVLO and 8 opened new positions — a net loss of 19 holders — while 20 trimmed existing stakes and 10 added.
The largest buyer was Flagship Pioneering, adding an estimated $63.5M. The largest seller was BlackRock, cutting an estimated $2.67M.
- 46 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2022, down from 68 in Q1 2022.
- Funds reported $180M of Evelo Biosciences, Inc. Common Stock stock for Q2 2022, up 12% quarter-over-quarter.
- 8 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2022 and 27 closed out, a net change of -19 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2022 was Flagship Pioneering, an estimated $63.5M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2022.